Seagen loses arbitration against Daiichi Sankyo over drug technology – Reuters

Aug 12 (Reuters) – U.S. drugmaker Seagen Inc (SGEN.O) said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo (4568.T) over an agreement between the two companies for using its drug technology.
The companies have been locked in a legal battle over patents on Daiichi and AstraZeneca Plc's (AZN.L) breast-cancer drug Enhertu, which Seagen says violates its patents.
Seagen filed an arbitration demand in 2019, saying the technology used in Enhertu are improvements to its antibody-drug conjugate technology.
The company, which was reported to be an acquisition target for Merck & Co Inc (MRK.N), said the ownership of the technology was assigned to it under a 2008 agreement with Daiichi Sankyo.
In the patent fight, a Texas jury had in April awarded Seagen nearly $42 million from Daiichi Sankyo.
Shares of Seagen were down 2.4% at $169.89 in afternoon trading.
Our Standards: The Thomson Reuters Trust Principles.
Big Pharma spent more than any other industry to lobby Congress and federal agencies this year, a Reuters analysis shows, but still suffered a major defeat after failing to stop a bill that allows the government to negotiate prices on select drugs.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source

Leave a Reply

Your email address will not be published. Required fields are marked *